Every 10-Q that Cardiff Oncology, Inc. (CRDF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRDF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRDF filings page.
Cardiff Oncology, Inc. reported continued operating losses while progressing its lead PLK1 inhibitor, onvansertib, through Phase 2 development in RAS-mutated metastatic colorectal cancer and other investigator-initiated trials. For the quarter ended June 30, 2026, royalty revenue was $104,000 and net loss was $9.2 million, compared with $13.9 million a year earlier, as research and development expenses fell to $5.9 million from $11.6 million due to trial completions and reduced preclinical work.
For the first six months of 2026, net loss was $21.6 million and operating cash outflows were $24.1 million. As of June 30, 2026, Cardiff held $34.5 million in cash, cash equivalents and short-term investments and disclosed that this is not sufficient to meet funding requirements for at least 12 months after issuance, leading management to conclude there is substantial doubt about its ability to continue as a going concern. Subsequent to quarter-end, the company raised $10.1 million in gross proceeds via a registered direct offering of common stock and warrants. Cardiff also highlighted ongoing litigation with its onvansertib licensor NMS regarding alleged termination of the license agreement, noting that an adverse outcome could materially impact its business.
Cardiff Oncology reported a net loss of $12.3 million for the quarter ended March 31, 2026, on royalty revenue of just $41,000. Operating expenses were $12.9 million, with research and development down to $6.8 million and selling, general and administrative expenses up to $6.1 million, largely from severance and stock-based compensation.
The company ended the quarter with $46.1 million in cash, cash equivalents and short‑term investments and used $12.3 million in operating cash, and management concluded there is substantial doubt about its ability to continue as a going concern beyond the next 12 months without new financing. Cardiff advanced its lead PLK1 inhibitor onvansertib, highlighting strong Phase 2 data in first‑line RAS‑mutated metastatic colorectal cancer and alignment with the FDA on a Phase 3 design, but also disclosed a license dispute with Nerviano that could, if unresolved, lead to termination of the onvansertib license and materially harm the business.
Cardiff Oncology (CRDF) reported Q3 2025 results with royalty revenue of $0.12M and a net loss of $11.3M (basic and diluted net loss per share $0.17). Research and development expense was $8.2M (down year over year), while selling, general and administrative expense was $3.9M (up year over year).
Cash, cash equivalents and short-term investments totaled $60.6M as of September 30, 2025. Net cash used in operating activities was $32.0M for the nine months. Management states current resources are sufficient for at least the next 12 months and, based on projections, to fund operations into the first quarter of 2027. Total stockholders’ equity was $48.8M.
In its lead mCRC program, Phase 2 CRDF-004 showed blinded independent central review ORR as of July 8, 2025: control 30%, onvansertib 20mg + SoC 42%, and onvansertib 30mg + SoC 49%. The combination was described as well-tolerated. Shares outstanding were 67,360,564 as of October 30, 2025.